Gang Pei
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Gang Pei has a total of 50 co-authors. Here are the top co-authors by number of shared publications:
- Yang Tan
School of Pharmacy, Hunan University of Chinese Medicine, Changsha, 410208, China; Key Laboratory of Modern Research of TCM, Education Department of Hunan Province, Changsha, 410208, China
7 shared publications Feng Zhou
School of Pharmacy, Hunan University of Chinese Medicine, Changsha, 410208, China; Key Laboratory of Modern Research of TCM, Education Department of Hunan Province, Changsha, 410208, China
5 shared publications- Feng Zhou
Hunan University of Chinese Medicine, Changsha, 410000, China; College of Pharmacy, Hunan University of Chinese Medicine, Changsha, 410000, China; Key Laboratory of Modern Research of TCM, Education Department of Hunan Province, Changsha, 410000, China
3 shared publications Xuebin Yang
College of Pharmacy, Hunan University of Chinese Medicine, Changsha, China
3 shared publicationsYang Tan
Pharmacy of College, Hunan University of Chinese Medicine, Changsha, China,; Key Laboratory of Modern Research of TCM, Education Department of Hunan Province, Changsha, China
3 shared publicationsChen Sun
Co-construction Collaborative Innovation Center for Chinese Medicine Resources Industrialization by Shaanxi & Education Ministry, Shaanxi University of Chinese Medicine, Xianyang, 712046, China
2 shared publications
Latest Publications
- Open Access
- 4 April 2026
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 366, 121652
Shaoyao Gancao Decoction alleviates ulcerative colitis-associated secondary liver injury by inhibiting the phosphorylation of pyruvate dehydrogenase in macrophages
- 4 April 2026
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 366, 121652
Open AccessShaoyao Gancao Decoction alleviates ulcerative colitis-associated secondary liver injury by inhibiting the phosphorylation of pyruvate dehydrogenase in macrophages
- Open Access
- 31 March 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Pomolic acid alleviates CCl4‑induced liver fibrosis in mice by suppressing β-arrestin 2-mediated pro-fibrotic macrophage polarization
Liver fibrosis is a wound healing process in response to various chronic liver injuries characterized by the replacement of normal liver by collagen fibers formed from extracellular matrix (ECM), resulting in scarring of the organ. Liver macrophages, a highly heterogeneous and plastic immune cell population, are pivotal in human health and disease, widely involved in the advancement and reversal of liver fibrosis. Interleukin-4 (IL-4) and/or interleukin-13 (IL-13)-induced pro-fibrotic macrophage polarization play a crucial role in promoting liver fibrosis through the secretion of transforming growth factor-β (TGF-β), a key profibrotic cytokine. This study aimed to explore the therapeutic potential and underlying mechanism of pomolic acid (PA) in mitigating carbon tetrachloride (CCl4)-induced liver fibrosis. The results indicated that PA effectively hindered pro-fibrotic macrophage polarization and the release of TGF-β, thereby ameliorating the fibrotic progression. Mechanistically, PA disrupted β-arrestin 2-IRG1 interaction, consequently impeding the ubiquitination-related degradation of IRG1, and ultimately suppressed fatty acid oxidation (FAO)-mediated pro-fibrotic macrophage polarization. Furthermore, PA also demonstrated excellent efficacy in combating oral submucosal fibrosis (OSF). In conclusion, our study confirmed that PA inhibited the advancement of fibrosis by repressing β-arrestin 2-induced pro-fibrotic macrophage polarization. These findings suggest that PA could serve as a promising and broad-spectrum anti-fibrotic drug.
- 31 March 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Open AccessPomolic acid alleviates CCl4‑induced liver fibrosis in mice by suppressing β-arrestin 2-mediated pro-fibrotic macrophage polarization
Liver fibrosis is a wound healing process in response to various chronic liver injuries characterized by the replacement of normal liver by collagen fibers formed from extracellular matrix (ECM), resulting in scarring of the organ. Liver macrophages, a highly heterogeneous and plastic immune cell population, are pivotal in human health and disease, widely involved in the advancement and reversal of liver fibrosis. Interleukin-4 (IL-4) and/or interleukin-13 (IL-13)-induced pro-fibrotic macrophage polarization play a crucial role in promoting liver fibrosis through the secretion of transforming growth factor-β (TGF-β), a key profibrotic cytokine. This study aimed to explore the therapeutic potential and underlying mechanism of pomolic acid (PA) in mitigating carbon tetrachloride (CCl4)-induced liver fibrosis. The results indicated that PA effectively hindered pro-fibrotic macrophage polarization and the release of TGF-β, thereby ameliorating the fibrotic progression. Mechanistically, PA disrupted β-arrestin 2-IRG1 interaction, consequently impeding the ubiquitination-related degradation of IRG1, and ultimately suppressed fatty acid oxidation (FAO)-mediated pro-fibrotic macrophage polarization. Furthermore, PA also demonstrated excellent efficacy in combating oral submucosal fibrosis (OSF). In conclusion, our study confirmed that PA inhibited the advancement of fibrosis by repressing β-arrestin 2-induced pro-fibrotic macrophage polarization. These findings suggest that PA could serve as a promising and broad-spectrum anti-fibrotic drug.
- Open Access
- 10 November 2025
- Published by Springer Nature in Research Square
Pomolic acid alleviates CCl4‑induced liver fibrosis in mice by suppressing β-arrestin 2-mediated M2 macrophage polarization
Liver fibrosis is a wound healing process in response to various chronic liver injuries characterized by the replacement of normal liver by collagen fibers formed from extracellular matrix (ECM), resulting in scarring of the organ. Liver macrophages, a highly heterogeneous and plastic immune cell population, are pivotal in human health and disease, widely involved in the advancement and reversal of liver fibrosis. Interleukin-4 (IL-4) and/or interleukin-13 (IL-13)-induced M2 macrophages play a crucial role in promoting liver fibrosis through the secretion of transforming growth factor-β (TGF-β), a key profibrotic cytokine. This study aimed to explore the therapeutic potential and underlying mechanism of pomolic acid (PA) in mitigating carbon tetrachloride (CCl 4 )-induced liver fibrosis. The results indicated that PA effectively hindered M2 polarization and the release of TGF-β, thereby ameliorating the fibrotic progression. Mechanistically, PA disrupted β-arrestin 2-IRG1 interaction, consequently impeding the ubiquitination-related degradation of IRG1, and ultimately suppressed fatty acid oxidation (FAO)-mediated M2 polarization. Furthermore, PA also demonstrated excellent efficacy in combating oral submucosal fibrosis (OSF). In conclusion, our study confirmed that PA inhibited the advancement of fibrosis by repressing β-arrestin 2-induced M2 polarization. These findings suggest that PA could serve as a promising and broad-spectrum anti-fibrotic drug.
- 10 November 2025
- Published by Springer Nature in Research Square
Open AccessPomolic acid alleviates CCl4‑induced liver fibrosis in mice by suppressing β-arrestin 2-mediated M2 macrophage polarization
Liver fibrosis is a wound healing process in response to various chronic liver injuries characterized by the replacement of normal liver by collagen fibers formed from extracellular matrix (ECM), resulting in scarring of the organ. Liver macrophages, a highly heterogeneous and plastic immune cell population, are pivotal in human health and disease, widely involved in the advancement and reversal of liver fibrosis. Interleukin-4 (IL-4) and/or interleukin-13 (IL-13)-induced M2 macrophages play a crucial role in promoting liver fibrosis through the secretion of transforming growth factor-β (TGF-β), a key profibrotic cytokine. This study aimed to explore the therapeutic potential and underlying mechanism of pomolic acid (PA) in mitigating carbon tetrachloride (CCl 4 )-induced liver fibrosis. The results indicated that PA effectively hindered M2 polarization and the release of TGF-β, thereby ameliorating the fibrotic progression. Mechanistically, PA disrupted β-arrestin 2-IRG1 interaction, consequently impeding the ubiquitination-related degradation of IRG1, and ultimately suppressed fatty acid oxidation (FAO)-mediated M2 polarization. Furthermore, PA also demonstrated excellent efficacy in combating oral submucosal fibrosis (OSF). In conclusion, our study confirmed that PA inhibited the advancement of fibrosis by repressing β-arrestin 2-induced M2 polarization. These findings suggest that PA could serve as a promising and broad-spectrum anti-fibrotic drug.
- 10 September 2025
- Published by Elsevier in International Immunopharmacology
- Vol. 165, 115446
PNMA4 enhances anti-RNA virus immunity by promoting RIG-I signaling pathway
- 10 September 2025
- Published by Elsevier in International Immunopharmacology
- Vol. 165, 115446
PNMA4 enhances anti-RNA virus immunity by promoting RIG-I signaling pathway
- 8 August 2025
- Published by Elsevier in Phytomedicine
- Vol. 147, 157111
Benzoylpaeoniflorin alleviates ulcerative colitis by inhibiting ferroptosis through targeting phosphogluconic dehydrogenase
- 8 August 2025
- Published by Elsevier in Phytomedicine
- Vol. 147, 157111
Benzoylpaeoniflorin alleviates ulcerative colitis by inhibiting ferroptosis through targeting phosphogluconic dehydrogenase
- Open Access
- 29 July 2025
- Published by MDPI AG in Current Issues in Molecular Biology
- Vol. 47 (8) , 598
Salvianolic Acid B Attenuates Liver Fibrosis via Suppression of Glycolysis-Dependent m1 Macrophage Polarization
Liver fibrosis, a critical pathological feature of chronic liver injury, is closely associated with macrophage-mediated inflammatory responses and metabolic reprogramming. Blocking the fibrosis process will be beneficial to the treatment and recovery of the disease. Liver macrophages are a remarkably heterogeneous population of immune cells that play multiple functions in homeostasis and are central to liver fibrosis. Glycolysis-mediated macrophage metabolic reprogramming leads to an increase in the proportion of M1 macrophages and the release of pro-inflammatory cytokines. The present study aimed to investigate the therapeutic effect and mechanism of acid B (SAL B) against carbon tetrachloride (CCl4)-induced liver fibrosis. Here, we demonstrate that SAL B reduced the production of inflammatory factors in CCl4-induced liver fibrosis. Mechanistically, SAL B increased the expression of migration inhibitor 1 (MIG1) by inhibiting DNMT1-mediated methylation of the MIG1 promoter. Subsequently, MIG1 reduced the transcription of lactate dehydrogenase A (LDHA) and hexokinase 2 (HK2) which blocked glycolysis-mediated macrophage M1 polarization. In summary, our results suggested that SAL B is a promising intervention for ameliorating liver fibrosis.
- 29 July 2025
- Published by MDPI AG in Current Issues in Molecular Biology
- Vol. 47 (8) , 598
Open AccessSalvianolic Acid B Attenuates Liver Fibrosis via Suppression of Glycolysis-Dependent m1 Macrophage Polarization
Liver fibrosis, a critical pathological feature of chronic liver injury, is closely associated with macrophage-mediated inflammatory responses and metabolic reprogramming. Blocking the fibrosis process will be beneficial to the treatment and recovery of the disease. Liver macrophages are a remarkably heterogeneous population of immune cells that play multiple functions in homeostasis and are central to liver fibrosis. Glycolysis-mediated macrophage metabolic reprogramming leads to an increase in the proportion of M1 macrophages and the release of pro-inflammatory cytokines. The present study aimed to investigate the therapeutic effect and mechanism of acid B (SAL B) against carbon tetrachloride (CCl4)-induced liver fibrosis. Here, we demonstrate that SAL B reduced the production of inflammatory factors in CCl4-induced liver fibrosis. Mechanistically, SAL B increased the expression of migration inhibitor 1 (MIG1) by inhibiting DNMT1-mediated methylation of the MIG1 promoter. Subsequently, MIG1 reduced the transcription of lactate dehydrogenase A (LDHA) and hexokinase 2 (HK2) which blocked glycolysis-mediated macrophage M1 polarization. In summary, our results suggested that SAL B is a promising intervention for ameliorating liver fibrosis.
- Open Access
- 17 February 2025
- Published by Elsevier in European Journal of Pharmacology
- Vol. 995, 177353
Astragaloside IV prevents liver fibrosis by blocking glycolysis-mediated macrophage M1 polarization
- 17 February 2025
- Published by Elsevier in European Journal of Pharmacology
- Vol. 995, 177353
Open AccessAstragaloside IV prevents liver fibrosis by blocking glycolysis-mediated macrophage M1 polarization
- Open Access
Mechanism of Mulberry Leaves and Black Sesame in Alleviating Slow Transit Constipation Revealed by Multi-Omics Analysis
Traditional Chinese medicine (TCM) possesses the potential of providing good curative effects with no side effects for the effective management of slow transit constipation (STC), an intestinal disease characterized by colonic dyskinesia. Mulberry leaves (Morus alba L.) and black sesame (Sesamum indicum L.), referred to as SH, are processed and conditioned as per standardized protocols. SH has applications as food and medicine. Accordingly, we investigated the therapeutic potential of SH in alleviating STC. The analysis of SH composition identified a total of 504 compounds. The intervention with SH significantly improved intestinal motility, reduced the time for the first black stool, increased antioxidant activity, and enhanced water content, thereby effectively alleviating colon damage caused by STC. Transcriptome analysis revealed the SH in the treatment of STC related to SOD1, MUC2, and AQP1. The analysis of 16S rRNA gene sequences indicated notable differences in the abundance of 10 bacteria between the SH and model. Metabolomic analysis further revealed that SH supplementation increased the levels of nine metabolites associated with STC. Integrative analysis revealed that SH modulated amino acid metabolism, balanced intestinal flora, and targeted key genes (i.e., SOD1, MUC2, AQP1) to exert its effects. SH also inhibited the AQP1 expression and promoted SOD1 and MUC2 expression.
Open AccessMechanism of Mulberry Leaves and Black Sesame in Alleviating Slow Transit Constipation Revealed by Multi-Omics Analysis
Traditional Chinese medicine (TCM) possesses the potential of providing good curative effects with no side effects for the effective management of slow transit constipation (STC), an intestinal disease characterized by colonic dyskinesia. Mulberry leaves (Morus alba L.) and black sesame (Sesamum indicum L.), referred to as SH, are processed and conditioned as per standardized protocols. SH has applications as food and medicine. Accordingly, we investigated the therapeutic potential of SH in alleviating STC. The analysis of SH composition identified a total of 504 compounds. The intervention with SH significantly improved intestinal motility, reduced the time for the first black stool, increased antioxidant activity, and enhanced water content, thereby effectively alleviating colon damage caused by STC. Transcriptome analysis revealed the SH in the treatment of STC related to SOD1, MUC2, and AQP1. The analysis of 16S rRNA gene sequences indicated notable differences in the abundance of 10 bacteria between the SH and model. Metabolomic analysis further revealed that SH supplementation increased the levels of nine metabolites associated with STC. Integrative analysis revealed that SH modulated amino acid metabolism, balanced intestinal flora, and targeted key genes (i.e., SOD1, MUC2, AQP1) to exert its effects. SH also inhibited the AQP1 expression and promoted SOD1 and MUC2 expression.
- Open Access
Salvianolic Acid B Alleviates Liver Injury by Regulating Lactate-Mediated Histone Lactylation in Macrophages
Salvianolic acid B (Sal B) is the primary water-soluble bioactive constituent derived from the roots of Salvia miltiorrhiza Bunge. This research was designed to reveal the potential mechanism of Sal B anti-liver injury from the perspective of macrophages. In our lipopolysaccharide-induced M1 macrophage model, Sal B showed a clear dose-dependent gradient of inhibition of the macrophage trend of the M1 type. Moreover, Sal B downregulated the expression of lactate dehydrogenase A (LDHA), while the overexpression of LDHA impaired Sal B’s effect of inhibiting the trend of macrophage M1 polarization. Additionally, this study revealed that Sal B exhibited inhibitory effects on the lactylation process of histone H3 lysine 18 (H3K18la). In a ChIP-qPCR analysis, Sal B was observed to drive a reduction in H3K18la levels in the promoter region of the LDHA, NLRP3, and IL-1β genes. Furthermore, our in vivo experiments showed that Sal B has a good effect on alleviating CCl4-induced liver injury. An examination of liver tissues and the Kupffer cells isolated from those tissues proved that Sal B affects the M1 polarization of macrophages and the level of histone lactylation. Together, our data reveal that Sal B has a potential mechanism of inhibiting the histone lactylation of macrophages by downregulating the level of LDHA in the treatment of liver injury.
Open AccessSalvianolic Acid B Alleviates Liver Injury by Regulating Lactate-Mediated Histone Lactylation in Macrophages
Salvianolic acid B (Sal B) is the primary water-soluble bioactive constituent derived from the roots of Salvia miltiorrhiza Bunge. This research was designed to reveal the potential mechanism of Sal B anti-liver injury from the perspective of macrophages. In our lipopolysaccharide-induced M1 macrophage model, Sal B showed a clear dose-dependent gradient of inhibition of the macrophage trend of the M1 type. Moreover, Sal B downregulated the expression of lactate dehydrogenase A (LDHA), while the overexpression of LDHA impaired Sal B’s effect of inhibiting the trend of macrophage M1 polarization. Additionally, this study revealed that Sal B exhibited inhibitory effects on the lactylation process of histone H3 lysine 18 (H3K18la). In a ChIP-qPCR analysis, Sal B was observed to drive a reduction in H3K18la levels in the promoter region of the LDHA, NLRP3, and IL-1β genes. Furthermore, our in vivo experiments showed that Sal B has a good effect on alleviating CCl4-induced liver injury. An examination of liver tissues and the Kupffer cells isolated from those tissues proved that Sal B affects the M1 polarization of macrophages and the level of histone lactylation. Together, our data reveal that Sal B has a potential mechanism of inhibiting the histone lactylation of macrophages by downregulating the level of LDHA in the treatment of liver injury.
- Open Access
- 1 January 2023
- Published by SAGE Publications in Therapeutic Advances in Gastroenterology
- Vol. 16
NOD-like receptors mediate homeostatic intestinal epithelial barrier function: promising therapeutic targets for inflammatory bowel disease
Inflammatory bowel disease (IBD) is a chronic gastrointestinal inflammatory disease that involves host genetics, the microbiome, and inflammatory responses. The current consensus is that the disruption of the intestinal mucosal barrier is the core pathogenesis of IBD, including intestinal microbial factors, abnormal immune responses, and impaired intestinal mucosal barrier. Cumulative data show that nucleotide-binding and oligomerization domain (NOD)-like receptors (NLRs) are dominant mediators in maintaining the homeostasis of the intestinal mucosal barrier, which play critical roles in sensing the commensal microbiota, maintaining homeostasis, and regulating intestinal inflammation. Blocking NLRs inflammasome activation by botanicals may be a promising way to prevent IBD progression. In this review, we systematically introduce the multiple roles of NLRs in regulating intestinal mucosal barrier homeostasis and focus on summarizing the activities and potential mechanisms of natural products against IBD. Aiming to propose new directions on the pathogenesis and precise treatment of IBD
- 1 January 2023
- Published by SAGE Publications in Therapeutic Advances in Gastroenterology
- Vol. 16
Open AccessNOD-like receptors mediate homeostatic intestinal epithelial barrier function: promising therapeutic targets for inflammatory bowel disease
Inflammatory bowel disease (IBD) is a chronic gastrointestinal inflammatory disease that involves host genetics, the microbiome, and inflammatory responses. The current consensus is that the disruption of the intestinal mucosal barrier is the core pathogenesis of IBD, including intestinal microbial factors, abnormal immune responses, and impaired intestinal mucosal barrier. Cumulative data show that nucleotide-binding and oligomerization domain (NOD)-like receptors (NLRs) are dominant mediators in maintaining the homeostasis of the intestinal mucosal barrier, which play critical roles in sensing the commensal microbiota, maintaining homeostasis, and regulating intestinal inflammation. Blocking NLRs inflammasome activation by botanicals may be a promising way to prevent IBD progression. In this review, we systematically introduce the multiple roles of NLRs in regulating intestinal mucosal barrier homeostasis and focus on summarizing the activities and potential mechanisms of natural products against IBD. Aiming to propose new directions on the pathogenesis and precise treatment of IBD